3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
1
Status
Recruiting
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
8
Gastrointestinal
3
Head & Neck
2
Conditions
Colorectal Neoplasms
3
Interventions
Fluorouracil
56
Specimen Handling
51
Oxaliplatin
49
Leucovorin
46
Magnetic Resonance Spectroscopy
45
Bevacizumab
43
Gemcitabine
39
Irinotecan
30
Cetuximab
27
Nivolumab
25
130-nm albumin-bound paclitaxel
25
Cisplatin
24
Biopsy
24
pembrolizumab
22
Paclitaxel
22
Capecitabine
19
atezolizumab
18
durvalumab
14
Taxes
14
Folfox protocol
14
Carboplatin
13
X-Rays
12
Radiotherapy
12
Cyclophosphamide
12
fludarabine
11
dehydroftorafur
10
Radiation
10
Albumin-Bound Paclitaxel
10
Surgical Procedures, Operative
9
Immunoglobulin G
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
amivantamab
×
Gastrointestinal
×
30 days
×
Clear all
NCT05379595
2026-06-05
OrigAMI-1
Janssen Research & Development, LLC
Phase 1/2
Recruiting
225 enrolled
NCT06662786
2026-06-05
OrigAMI-2
Janssen Research & Development, LLC
Phase 3
Recruiting
1,000 enrolled
NCT06750094
2026-06-05
OrigAMI-3
Janssen Research & Development, LLC
Phase 3
Recruiting
700 enrolled